Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Cells were stained with CD19, 7-AAD, and anti-Annexin V-PE diluted 1:200 (BioLegend, 640908) for 20 min, RT
Combined bisulfite restriction analysis The DNA methylation status of each individual locus was investigated by combined bisulfite restriction analysis (COBRA) and bisulfite sequencing (BSS)
The manufacturer stopped making this drug in 2006, and it is no longer FDA-approved for this purpose
Results from combined microneedling and copper peptide protocols consistently exceed either treatment alone
(2) the specific CI inhibitor IACS-010759 was recently reported to promote neurotoxicity, making this an unattractive agent for combination therapy in CRC given the neurotoxicity long-recognized with oxaliplatin treatment 51
US$ 26.98
US$ 22.49
US$ 29.18
